Source: Healio News
The addition of daratumumab to pomalidomide and dexamethasone extended PFS among patients with relapsed or refractory multiple myeloma who were refractory to lenalidomide, according to a study presented at ASH Annual Meeting and Exposition.
The safety profile of the combination appeared consistent with previous reports for subcutaneous daratumumab (Darzalex, Janssen), pomalidomide (Pomalyst, Bristol Myers Squibb) and dexamethasone, results of the phase 3 APOLLO study showed.
“In the primary analysis of the phase 3 APOLLO study, with median follow-up of 16.9 months, the addition of